- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.11.25 | UNICEF and Gavi to widen affordable malaria vaccine access | ||
| 26.11.25 | FDA grants accelerated approval for Otsuka's IgAN therapy | ||
| 25.11.25 | Gilead snaps up Sprint's TREX1 immunotherapy programme for $400m | ||
| 25.11.25 | UK-developed leukaemia cell therapy to be offered on NHS | ||
| 25.11.25 | Made Scientific and Cellergy partner to advance CLG-001 | ||
| 25.11.25 | Novartis secures approval from FDA for Itvisma to treat SMA | ||
| 24.11.25 | GLP-1RA Alzheimer's hopes dashed after Novo Nordisk's semaglutide miss | ||
| 24.11.25 | Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club | ||
| 24.11.25 | Navigating the FDA's import operations for pharmaceuticals and biologics | ||
| 24.11.25 | Investors bet on newer technology and indications for CGTs | ||
| 24.11.25 | AstraZeneca to expand biomanufacturing in Maryland, US | ||
| 24.11.25 | Vaximm and BCME link on oral cancer immunotherapy platform | ||
| 21.11.25 | "Reckless and harmful": experts weigh in on CDC's autism-vaccine link stance | ||
| 21.11.25 | Early planning, outsourcing and digitalisation to break down CGT CMC barriers | ||
| 21.11.25 | Aspen closes $115m in Series C to advance Parkinson's cell therapy | ||
| 21.11.25 | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | ||
| 20.11.25 | CPHI 2025: linker innovation paves the way for a wave of new ADCs | ||
| 20.11.25 | Merck KGaA eyes new Parkinson's disease assets with $3bn Valo partnership | ||
| 20.11.25 | Moderna to onshore drug product manufacturing to Massachusetts | ||
| 20.11.25 | Regeneron's Eylea franchise boosted by pair of FDA approvals | ||
| 20.11.25 | Novartis taps North Carolina as new manufacturing hub location | ||
| 20.11.25 | Pfizer and Tris agree with Texas over ADHD drug allegations | ||
| 20.11.25 | EC authorises Roche's Lunsumio SC for follicular lymphoma | ||
| 19.11.25 | Alkermes prevails over Lundbeck in Avadel bidding war | ||
| 19.11.25 | Arrowhead nets first commercial win as siRNA drug garners FDA approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .